NYMXFOTCIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
NYMOX PHARMACEUTICAL CORP
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Sep 14, 2026
$0.04+0.00 (0.00%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
Nymox Pharmaceutical statistics
Financials through Dec 31, 2025, price as of Oct 19, 2026, median of In Vitro & In Vivo Diagnostic Substances companies for comparison
Valuation
| Measure | Nymox Pharmaceutical | Industry median |
|---|---|---|
| Market Cap | $4.29M | $166.30M |
| Enterprise Value | $4.29M | $88.19M |
Income (trailing twelve months)
| Measure | Nymox Pharmaceutical | Industry median |
|---|---|---|
| Revenue | $0 | $58.34M |
| Gross Profit | $0 | $105.94M |
| Operating Income | -$3.68M | -$21.40M |
| Pretax Income | -$4.28M | -$14.34M |
| Net Income | -$4.28M | -$22.46M |
| EBITDA | -$3.68M | -$16.91M |
| EPS (Diluted) | -$0.05 | -$0.83 |
Returns
| Measure | Nymox Pharmaceutical | Industry median |
|---|---|---|
| Return on Assets (ROA) | -695.1% | -40.9% |
Balance sheet
| Measure | Nymox Pharmaceutical | Industry median |
|---|---|---|
| Working Capital | -$9.31M | $76.81M |
Financial position
| Measure | Nymox Pharmaceutical | Industry median |
|---|---|---|
| Current Ratio | 0.06 | 3.34 |
| Interest Coverage | -6.26 | -6.26 |
Cash flow (trailing twelve months)
| Measure | Nymox Pharmaceutical | Industry median |
|---|---|---|
| Operating Cash Flow | -$1.81M | -$12.35M |
| Capital Expenditures | $1.00K | -$1.08M |
| Free Cash Flow | -$1.81M | -$20.22M |
| FCF Per Share | -$0.02 | -$0.42 |
Efficiency
| Measure | Nymox Pharmaceutical | Industry median |
|---|---|---|
| Asset Turnover | 0.00 | 0.39 |
| Revenue Per Employee | $0 | $404.87K |
| Profits Per Employee | -$1.43M | -$703.34K |
| Employee Count | 3 | 74 |
Dividends and yields
| Measure | Nymox Pharmaceutical | Industry median |
|---|---|---|
| Earnings Yield | -99.8% | -23.3% |
| FCF Yield | -42.1% | -8.72% |
| Buyback Yield | 0.00% | -0.59% |
| Shareholder Yield | 0.00% | 0.00% |
Shares
| Measure | Nymox Pharmaceutical | Industry median |
|---|---|---|
| Shares Outstanding | 102,040,000 | 58,127,000 |
| Shares Change (YoY) | 2.53% | 10.9% |
| Float | 102,040,000 | 49,136,700 |
| Shares Held by Insiders | 0.00% | 11.6% |
Taxes
| Measure | Nymox Pharmaceutical | Industry median |
|---|---|---|
| Income Tax | $0 | $79.87K |
Scores
| Measure | Nymox Pharmaceutical | Industry median |
|---|---|---|
| Altman Z-Score | -567.01 | -0.22 |
| Piotroski F-Score | 3 | 4 |
Calculated by StockData from Nymox Pharmaceutical's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.